RPRX Royalty Pharma Plc

$39.46

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 11/18/2025

About Royalty Pharma Plc

Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.

Website: https://www.royaltypharma.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1802768
Address
110 EAST 59TH STREET, NEW YORK, NY, US
Valuation
Market Cap
$18.72B
P/E Ratio
17.07
PEG Ratio
2.28
Price to Book
2.03
Performance
EPS
$1.91
Dividend Yield
2.70%
Profit Margin
38.00%
ROE
13.00%
Technicals
50D MA
$32.55
200D MA
$28.79
52W High
$34.20
52W Low
$23.89
Fundamentals
Shares Outstanding
433M
Target Price
$40.03
Beta
0.49

RPRX EPS Estimates vs Actual

● Estimated
● Actual

RPRX News & Sentiment

Nov 12, 2025 • GlobeNewswire NEUTRAL
Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease ( IgG4-RD ) expected around ...
Nov 11, 2025 • Motley Fool SOMEWHAT-BULLISH
Here's Why Shares in Theravance Biopharma Exploded Today
The company is making excellent progress on all its strategic goals.
Nov 06, 2025 • Motley Fool SOMEWHAT-BULLISH
Cytokinetics ( CYTK ) Q3 2025 Earnings Transcript
Image source: The Motley Fool.Wednesday, Nov. 5, 2025 at 4:30 p.m. ETPresident & Chief Executive Officer - Robert I. BlumContinue reading ...
Nov 06, 2025 • Motley Fool SOMEWHAT-BULLISH
Revolution Medicines ( RVMD ) Earnings Transcript
Image source: The Motley Fool.Wednesday, Nov. 5, 2025 at 4:30 p.m. ETChief Executive Officer - Mark A. GoldsmithContinue reading ...
Nov 05, 2025 • Benzinga NEUTRAL
Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update - Cytokinetics ( NASDAQ:CYTK )
Interactions with FDA Progressing Towards December 26, 2025 PDUFA Date for Aficamten; U.S. Commercial Launch Preparations on Track Ex-U.S. Regulatory Reviews of Aficamten Ongoing in China and E.U. ~$1.25 Billion in Cash, Cash Equivalents and Investments as of September 30, 2025
Nov 05, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Royalty Pharma ( RPRX ) Beats Q3 Earnings and Revenue Estimates
Royalty Pharma (RPRX) delivered earnings and revenue surprises of +5.41% and +1.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Sentiment Snapshot

Average Sentiment Score:

0.259
50 articles with scored sentiment

Overall Sentiment:

Bullish

RPRX Reported Earnings

Aug 06, 2025
Jun 30, 2025 (Pre market)
0.11 Surprise
  • Reported EPS: $1.14
  • Estimate: $1.03
  • Whisper: —
  • Surprise %: 10.7%
May 08, 2025
Mar 31, 2025 (Pre market)
0.11 Surprise
  • Reported EPS: $1.06
  • Estimate: $0.95
  • Whisper: —
  • Surprise %: 11.6%
Feb 11, 2025
Dec 31, 2024 (Pre market)
0.1 Surprise
  • Reported EPS: $0.35
  • Estimate: $0.25
  • Whisper: —
  • Surprise %: 40.0%
Nov 06, 2024
Sep 30, 2024 (Pre market)
-0.01 Surprise
  • Reported EPS: $0.92
  • Estimate: $0.93
  • Whisper: —
  • Surprise %: -1.1%
Aug 08, 2024
Jun 30, 2024 (Pre market)
-0.01 Surprise
  • Reported EPS: $0.96
  • Estimate: $0.97
  • Whisper: —
  • Surprise %: -1.0%
May 09, 2024
Mar 31, 2024 (Pre market)
0.0 Surprise
  • Reported EPS: $0.98
  • Estimate: $0.98
  • Whisper: —
  • Surprise %: 0.0%
Feb 15, 2024
Dec 31, 2023 (Pre market)
0.52 Surprise
  • Reported EPS: $1.52
  • Estimate: $1.00
  • Whisper: —
  • Surprise %: 52.0%
Nov 08, 2023
Sep 30, 2023 (Pre market)
0.02 Surprise
  • Reported EPS: $0.79
  • Estimate: $0.77
  • Whisper: —
  • Surprise %: 2.6%
Aug 08, 2023
Jun 30, 2023 (Pre market)
0.03 Surprise
  • Reported EPS: $0.84
  • Estimate: $0.81
  • Whisper: —
  • Surprise %: 3.7%

Financials